PHARMACEUTICAL giant Pfizer
has won its battle to retain the
validity of its patent on its US$4.6b
neuropathic pain therapy Lyrica
(pregabalin) in the US Court of
Appeals for the Federal Circuit in
Washington this week.
As well as neuropathic pain such
as that that from shingles and
fibromyalgia, Lyrica is also used to
treat epilepsy and hot flashes and
according to a Bloomberg report,
contributes around 9% of Pfizer’s
total revenue.
Four companies were involved in
the patent challenge: Teva, Actavis,
Lupin and Sun Pharmaceuticals.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.